- Lobbying
- Lobbying by OncoSec Medical Inc.
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Chris Jones | Chief of Staff, Rep. Mike Ferguson; 2001-2009; Deputy Chief of Staff, Rep. David McIntosh, 1995-2001; Communications Director, House Government Reform and Oversight Subcommittee, 1996-2001; Press Secretary, Rep. John Myers, 1994-1995. Chief of Staff, Rep. Mike Ferguson 2001-2009; Deputy Chief of Staff, Rep. David McIntosh 1995-2001; Communications Director, House Government Reform and Oversight Subcommittee 1996-2001; Press Secretary, Rep. John Myers 1994-1995. |
Adam Higgins | Legislative Assistant, Rep. Mike Ferguson, 2007-2008. Legislative Assistant, Rep. Mike Ferguson 2007-2008. |
Tyler Thompson | Legislative Assistant, Sen. Johnny Isakson, 2005-2012; Legislative Correspondent, Sen. Saxby Chambliss, 2005-2005; Legislative Correspondent, Sen. Zell Miller, 2002-2005. Legislative Assistant, Sen. Johnny Isakson 2005-2012; Legislative Correspondent, Sen. Saxby Chambliss 2005-2005; Legislative Correspondent, Sen. Zell Miller 2002-2005. |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Registration
Issue(s) they said they’d lobby about: Regulatory and reimbursement policy issues relating to immunotherapy..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate